Cases & Deals

Isis Pharmaceuticals establishes patent portfolio for antisense oligonucleotides directed to IL-4R alpha

Clients Isis Pharmaceuticals, Inc.

Jones Day assisted Isis Pharmaceuticals, Inc. in the development of a global patent portfolio related to antisense oligonucleotides and other oligomeric compounds that target interleukin-4 receptor alpha (IL-4Ra), as well as uses of those compounds for the prevention and treatment of various conditions associated with expression of IL-4Ra, such as pulmonary inflammation and airway hyperresponsiveness.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.